

James Larkin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/272595/james-larkin-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

44,926
citations

52
h-index

172
g-index

172
ext. papers

56,071
ext. citations

13.8
avg, IF

6.85
L-index

#	Paper	IF	Citations
151	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101701	2.2	2
150	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.. <i>Expert Review of Anticancer Therapy</i> , 2022 , 1-9	3.5	1
149	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 306-306	2.2	0
148	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101090	2.2	0
147	Reply to T. Olivier et al.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200209	2.2	
146	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101806	2.2	1
145	Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. <i>European Journal of Cancer</i> , 2022 , 165, 97-112	7.5	0
144	Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. <i>Cancer Research</i> , 2022 , 82, A012-A012	10.1	
143	Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. <i>Cancer Research</i> , 2022 , 82, PR002-PR002	10.1	
142	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 2021 , 9,		2
141	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021 , 158, 156-168	7.5	5
140	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
139	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021 , 39, 1497-1518.e11	24.3	14
138	Reply to E. Hindi <i>Journal of Clinical Oncology</i> , 2021 , 39, 944-946	2.2	
137	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1020-1028	2.2	26
136	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2021 , 79, 4-4	12.7	17
135	CACtUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS9587-TPS9587	2.2	1

134	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 655-664	21.7	9
133	Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9574-9574	2.2	1
132	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4547-4547	2.2	1
131	Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9505-9505	2.2	4
130	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4579-4579	2.2	
129	Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9569-9569	2.2	1
128	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 643-654	21.7	58
127	5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021 ,	12.9	10
126	Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. <i>Lancet Oncology, The</i> , 2021 , 22, 905-907	21.7	1
125	Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) 2021 ,		11
124	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab 2021 , 9,		1
123	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 36-48	2.4	61
122	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021 , 124, 237-246	8.7	5
121	Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. <i>Cells</i> , 2021 , 10,	7.9	7
120	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021 , 31, 181-185	3.3	3
119	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021 , 184, 596-614.e14	56.2	144
118	Activation and transcriptional profile of monocytes and CD8 T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021 , 75, 177-189	13.4	7
117	Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2021 , 62, 403-406	1.3	1

116	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2656-2666	2.2	35
115	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021 , 9, 1202-1213	12.5	11
114	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021 , 108, 106481	2.3	1
113	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021 , 108, 106482	2.3	8
112	Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. <i>European Journal of Cancer</i> , 2021 , 156, 187-189	7.5	0
111	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.. <i>Nature Ecology and Evolution</i> , 2021 ,	12.3	4
110	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 739-753	5.9	2
109	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 679-697	18.8	9
108	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020 , 26, 4201-4205	12.9	25
107	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020 , 31, 107550	10.6	19
106	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020 , 130, 126-138	7.5	39
105	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 519-527	13.4	148
104	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4064-4075	2.2	25
103	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020 , 126, 4156-4167	6.4	66
102	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020 , 16, 2165-2175	3.6	9
101	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020 , 11, 3800	17.4	21
100	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020 , 5,	6	12
99	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1139-1148	59.2	105

98	Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1465-1477	21.7	140
97	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3925-3936	2.2	78
96	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. <i>European Urology Focus</i> , 2020 , 6, 999-1005	5.1	3
95	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020 , 28, 561-570	3.9	19
94	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 343-354	3.5	
93	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
92	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019 , 109, 61-69	7.5	18
91	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 207-215	7.5	26
90	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 148-157	7.5	42
89	Genomic Features of Exceptional Response in Vemurafenib + Cobimetinib-treated Patients with -mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 3239-3246	12.9	23
88	Reply to E. Hindil and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1356-1358	2.2	1
87	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 380, 1103-1115	59.2	1069
86	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7	88
85	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2019 , 19, 1102	4.8	7
84	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2	918
83	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. <i>Cell</i> , 2018 , 173, 581-594.e12	56.2	350
82	BMI and outcomes in melanoma: more evidence for the obesity paradox. <i>Lancet Oncology, The</i> , 2018 , 19, 269-270	21.7	11
81	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 1382-1388	13.4	42

80	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918777427	5.4	5
79	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018 , 91, 168-170	7.5	23
78	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 383-390	2.2	273
77	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3441-3449	2.2	137
76	PTU-009 Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea 2018 ,		2
75	Elevated Levels of Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-17	3.6	2
74	Effects of Molecular Heterogeneity on Survival of Patients With -Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-18	3.6	2
73	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1480-1492	21.7	680
72	Immune checkpoint inhibitors and cardiovascular toxicity. <i>Lancet Oncology</i> , 2018 , 19, e447-e458	21.7	221
71	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018 , 74, 611-620	10.2	49
70	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 226-235	2.2	302
69	Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 251-262	3.8	3
68	Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17009	51.1	963
67	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. <i>European Journal of Cancer</i> , 2017 , 80, 55-62	7.5	11
66	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017 , 8, 15724	17.4	50
65	Gene Expression Profiling in -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. <i>Clinical Cancer Research</i> , 2017 , 23, 5238-5245	12.9	30
64	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 647-655	3.5	10
63	Reply to Comment on Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2017 , 116, e15	8.7	1

62	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 785-792	2.2	696
61	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3807-3814	2.2	264
60	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. <i>European Journal of Cancer</i> , 2017 , 83, 247-257	7.5	181
59	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1813-1823	59.2	778
58	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1824-1835	59.2	1178
57	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
56	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017 , 390, 1853-1862	4.0	703
55	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology, The</i> , 2017 , 18, 1009-1021	21.7	492
54	Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. <i>Translational Oncology</i> , 2017 , 10, 679-685	4.9	5
53	The safety of nivolumab for the treatment of metastatic melanoma. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 955-961	4.1	6
52	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. <i>JAMA Oncology</i> , 2017 , 3, 1511-1519	13.4	101
51	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91	7.5	55
50	The combination of vemurafenib and cobimetinib in advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 1105-1111	1.1	3
49	Recent developments in melanoma management. <i>Trends in Urology & Men's Health</i> , 2016 , 7, 8-12	0.3	
48	Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. <i>Lancet Oncology, The</i> , 2016 , 17, e4-5	21.7	86
47	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 389-96	5.4	29
46	Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 92-100	4.5	34
45	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. <i>Journal of the National Cancer Institute</i> , 2016 , 108, djv414	9.7	70

44	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016 , 53, 125-34	7.5	115
43	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 167.e17-23	2.8	15
42	A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9597-TPS9597	2.2	2
41	Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1248-60	21.7	590
40	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. <i>Cancer Cell</i> , 2015 , 27, 240-56	24.3	226
39	Translational implications of tumor heterogeneity. <i>Clinical Cancer Research</i> , 2015 , 21, 1258-66	12.9	292
38	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. <i>JAMA Oncology</i> , 2015 , 1, 433-40	13.4	160
37	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 833-40	7.5	60
36	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015 , 372, 2521-32	59.2	3792
35	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 375-84	21.7	1881
34	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. <i>Nature Communications</i> , 2015 , 6, 6336	17.4	85
33	Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin α /FAK signaling. <i>Cancer Cell</i> , 2015 , 27, 574-88	24.3	366
32	Relapse models for clear cell renal carcinoma. <i>Lancet Oncology, The</i> , 2015 , 16, e376-8	21.7	2
31	Pembrolizumab in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015 , 2, 315-325	2.1	4
30	Pazopanib-induced alopecia, an underestimated toxicity?. <i>Frontiers in Oncology</i> , 2015 , 5, 112	5.3	2
29	Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data. <i>Frontiers in Oncology</i> , 2015 , 5, 195	5.3	5
28	Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e239-47	7.1	7
27	Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC. <i>Nature Reviews Urology</i> , 2015 , 12, 309-19	9.5	5

26	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
25	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	40	926
24	Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015 , 51, 2785-91	7.5	38
23	SnapShot: Renal Cell Carcinoma. <i>Cell</i> , 2015 , 163, 1556-1556.e1	56.2	41
22	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1473-1482	21.7	575
21	PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. <i>European Journal of Cancer</i> , 2015 , 51, 359-66	7.5	18
20	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology, The</i> , 2015 , 16, 15-7	21.7	9
19	Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer. <i>PLoS ONE</i> , 2015 , 10, e0122589	3.7	15
18	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1867-76	59.2	1403
17	Systemic anti-cancer therapy (SACT) dataset. <i>Lancet Oncology, The</i> , 2014 , 15, 1063	21.7	3
16	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1877-88	59.2	1195
15	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , 2014 , 15, 323-32	21.7	753
14	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology, The</i> , 2014 , 15, 436-44	21.7	206
13	Advances in immunotherapy for melanoma. <i>Melanoma Management</i> , 2014 , 1, 19-24	2.1	
12	Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. <i>European Urology</i> , 2014 , 66, 936-48	10.2	109
11	Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 397-403	2.7	12
10	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. <i>Nature Genetics</i> , 2014 , 46, 225-233	36.3	866
9	Individualising treatment choices in a crowded treatment algorithm. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 160-8	1.6	2

8	Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. <i>Human Molecular Genetics</i> , 2013 , 22, 825-31	5.6	49
7	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. <i>New England Journal of Medicine</i> , 2012 , 366, 883-892	59.2	5559
6	Epigenetic regulation in RCC: opportunities for therapeutic intervention?. <i>Nature Reviews Urology</i> , 2012 , 9, 147-55	5.5	41
5	Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. <i>Anticancer Research</i> , 2012 , 32, 2399-406	2.3	9
4	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
3	Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 639-49	3.5	13
2	Is advanced renal cell carcinoma becoming a chronic disease?. <i>Lancet, The</i> , 2010 , 376, 574-5	4.0	10
1	Advances in the Management of Metastatic Renal Cell Cancer. <i>European Urology Supplements</i> , 2009 , 8, 758-761	0.9	